09/28/23 8:30 AMNasdaq : VCEL clinical trialVericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBridData published in the Journal of Burn Care & Research show treatment with NexoBrid resulted in early complete eschar removal in more than 90% of treated patients, and reduced surgery when compared to Gel Vehicle and standard of care Results demonstrate that NexoBrid is safe and well-toleratedRHEA-AIneutral
09/20/23 4:30 PMNasdaq : VCEL Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in AdultsFull commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns NexoBrid launch significantly expands the total addressable market for Vericel Burn Care CAMBRIDGE, Mass., Sept.RHEA-AIneutral
09/06/23 8:30 AMNasdaq : VCEL conferencesVericel to Present at the Morgan Stanley Global Healthcare ConferenceVericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will participate in a fireside chat at the Morgan Stanley 21 stRHEA-AIneutral
08/02/23 7:55 AMNasdaq : VCEL earningsVericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial GuidanceRecord Second Quarter Total Revenue of $45.9 Million, Representing 24% Growth versus Prior Year MACI Revenue Growth of 27% to $36.3 Million Epicel Revenue Growth of 17% to $9.6 Million Full-Year 2023 Revenue Guidance Raised to $190-197 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE,RHEA-AIneutral
07/20/23 8:30 AMNasdaq : VCEL conferencesearningsVericel to Report Second-Quarter 2023 Financial Results on August 2, 2023Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2023 financial results on Wednesday, August 2, 2023. Vericel’sRHEA-AIneutral
05/10/23 7:55 AMNasdaq : VCEL earningsVericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial GuidanceVericel Corporation (NASDAQ:VCEL), a leader inRHEA-AIneutral
05/02/23 9:00 AMNasdaq : VCEL, SGTX Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior AdvisorDimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D., to the board of directors and Chris Ehrlich as Senior Advisor. Dr. Wotton fills the roleRHEA-AIvery positive
04/26/23 8:30 AMNasdaq : VCEL conferencesearningsVericel to Report First-Quarter 2023 Financial Results on May 10, 2023Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2023 financial results on Wednesday, May 10, 2023. Vericel’sRHEA-AIneutral
02/28/23 8:30 AMNasdaq : VCEL conferencesVericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. TheRHEA-AIneutral
02/23/23 7:55 AMNasdaq : VCEL earningsVericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial GuidanceRecord Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth Full-Year 2022 Total Revenue of $164.4 Million, with MACI Revenue of $132 Million Full-Year 2023 Total Revenue Guidance of $180 to $188 Million, with MACI Revenue of $152 to $156 Million Conference Call Today at 8:30amRHEA-AIpositive